Inhibition of Allogeneic and Autologous T Cell Proliferation by Adipose-Derived Mesenchymal Stem Cells of Ankylosing Spondylitis Patients.
Ewa Kuca WarnawinMagdalena PlebańczykKrzysztof BonekEwa KontnyPublished in: Stem cells international (2021)
We report for the first time that despite chronic in vivo exposure to inflammatory conditions, AS/ASCs retain the normal capability to restrain expansion of allogeneic and autologous CD4+ and CD8+ T cells, act primarily via kynurenines and PGE2, and thus may have potential therapeutic value. Some distinctions between the antiproliferative effects of AS/ASCs and HD/ASCs suggest in vivo licensing of AS/ASCs.
Keyphrases
- bone marrow
- ankylosing spondylitis
- mesenchymal stem cells
- stem cell transplantation
- cell proliferation
- end stage renal disease
- cell therapy
- ejection fraction
- rheumatoid arthritis
- chronic kidney disease
- newly diagnosed
- disease activity
- peritoneal dialysis
- prognostic factors
- oxidative stress
- platelet rich plasma
- hematopoietic stem cell
- systemic lupus erythematosus
- high dose
- pi k akt
- low dose